Hepatocellular carcinoma
Conditions
Brief summary
Per-lesion detection rate of F-18 PSMA-11 PET/CT, 60-90 minutes post-injection.
Detailed description
Overall Survival (OS) and Progression-Free Survival (PFS): Measured among subjects with PSMA-avid, FDG-avid, and Choline-avid HCC lesions, measured after completion of the 2 year follow-up for all patients., Tumor-to-Background Ratio: Assessed for intrahepatic HCC lesions 60-90 minutes post-injection using F-18 PSMA-11 PET/CT., Standard Uptake Value (SUV) Parameters: Analyzed for all HCC lesions detected 60-90 minutes post-injection with F-18 PSMA-11 PET/CT., Proportion of subjects with Metastatic HCC: Comparison between those detected by F-18 PSMA-11 PET/CT, F-18 FDG PET, and F-18 Choline PET, 60-90 minutes post-injection.
Interventions
DRUG[18F]PSMA-11
Sponsors
Universitair Ziekenhuis Gent
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Per-lesion detection rate of F-18 PSMA-11 PET/CT, 60-90 minutes post-injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) and Progression-Free Survival (PFS): Measured among subjects with PSMA-avid, FDG-avid, and Choline-avid HCC lesions, measured after completion of the 2 year follow-up for all patients., Tumor-to-Background Ratio: Assessed for intrahepatic HCC lesions 60-90 minutes post-injection using F-18 PSMA-11 PET/CT., Standard Uptake Value (SUV) Parameters: Analyzed for all HCC lesions detected 60-90 minutes post-injection with F-18 PSMA-11 PET/CT., Proportion of subjects with Metastatic HCC: Comparison between those detected by F-18 PSMA-11 PET/CT, F-18 FDG PET, and F-18 Choline PET, 60-90 minutes post-injection. | — |
Countries
Belgium
Outcome results
None listed